APLS · Categories · Downgrades
APLS - Analyst downgrades
Apellis Pharmaceuticals Inc. (APLS) analyst downgrades - real-time wire coverage filtered to Downgrades only.
Recent Downgrades for APLS
- Apellis Pharmaceuticals downgraded by Goldman with a new price targetGoldman downgraded Apellis Pharmaceuticals from Neutral to Sell and set a new price target of $18.00
- Apellis Pharmaceuticals downgraded by Raymond James with a new price targetRaymond James downgraded Apellis Pharmaceuticals from Strong Buy to Outperform and set a new price target of $52.00
- Apellis Pharmaceuticals downgraded by BofA Securities with a new price targetBofA Securities downgraded Apellis Pharmaceuticals from Buy to Neutral and set a new price target of $23.00
- Apellis Pharmaceuticals downgraded by Goldman with a new price targetGoldman downgraded Apellis Pharmaceuticals from Buy to Neutral and set a new price target of $36.00
- Apellis Pharmaceuticals downgraded by Wells FargoWells Fargo downgraded Apellis Pharmaceuticals from Overweight to Equal Weight
- Apellis Pharmaceuticals downgraded by JP Morgan with a new price targetJP Morgan downgraded Apellis Pharmaceuticals from Overweight to Neutral and set a new price target of $60.00 from $72.00 previously
- Apellis Pharmaceuticals downgraded by BofA Securities with a new price targetBofA Securities downgraded Apellis Pharmaceuticals from Buy to Neutral and set a new price target of $40.00 from $114.00 previously
- Apellis Pharmaceuticals downgraded by Wells Fargo with a new price targetWells Fargo downgraded Apellis Pharmaceuticals from Overweight to Equal Weight and set a new price target of $58.00 from $83.00 previously
- Apellis Pharmaceuticals downgraded by Jefferies with a new price targetJefferies downgraded Apellis Pharmaceuticals from Buy to Hold and set a new price target of $40.00 from $70.00 previously
- Apellis Pharmaceuticals downgraded by ROTH Capital with a new price targetROTH Capital downgraded Apellis Pharmaceuticals from Neutral to Sell and set a new price target of $40.00
- Apellis Pharmaceuticals downgraded by ROTH Capital with a new price targetROTH Capital downgraded Apellis Pharmaceuticals from Buy to Neutral and set a new price target of $40.00 from $46.00 previously
- Apellis Pharmaceuticals downgraded by Wedbush with a new price targetWedbush downgraded Apellis Pharmaceuticals from Outperform to Neutral and set a new price target of $39.00 from $71.00 previously